bioRxivBiochemistry
A COVID Moonshot: assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy.
A. L. Kantsadi, E. Cattermole, M.-T. Matsoukas, G. A. Spyroulias, I. Vakonakis
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of the coronavirus disease 2019, for which no effective therapeutics are available. The SARS-CoV-2 main protease (Mpro) is essential for viral replication and constitutes a promising therapeutic target. Many efforts aimed at deriving effective Mpro inhibitors are currently underway, including an international open-science discovery project, codenamed COVID Moonshot. As part of COVID Moonshot, we used saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy to assess the binding of putative Mpro ligands to the viral protease, including molecules identified by crystallographic fragment screening and novel compounds designed as Mpro inhibitors. In this manner, we aimed to complement enzymatic activity assays of Mpro performed by other groups with information on ligand affinity. We have made the Mpro STD-NMR data publicly available. Here, we provide detailed information on the NMR protocols used and challenges faced, thereby placing these data into context. Our goal is to assist the interpretation of Mpro STD-NMR data, thereby accelerating ongoing drug design efforts.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 Main Protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Y. L. Weng, S. R. Naik, … A. Ganesan·bioRxiv·Oct 31, 2020
- Allosteric inhibition of the SARS-CoV-2 main protease - insights from mass spectrometry-based assays
T. J. El-Baba, C. A. Lutomski, … C. V. Robinson·bioRxiv·Jul 29, 2020
- High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor
A. Clyde, S. Galanie, … R. Stevens·bioRxiv·Mar 27, 2021
- Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease
D. W. Kneller, G. Phillips, … A. Kovalevsky·bioRxiv·Jan 12, 2021
- Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
E. A. Fink, C. Bardine, … C. S. Craik·bioRxiv·Jul 5, 2022
- Repurposing low-molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2